Centessa Pharmaceuticals (CNTA) Projected to Post Earnings on Monday

Centessa Pharmaceuticals (NASDAQ:CNTA) is anticipated to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Centessa Pharmaceuticals to post earnings of ($0.38) per share and revenue of $0.7670 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 3:00 AM ET.

Centessa Pharmaceuticals Trading Down 3.3%

CNTA stock opened at $26.33 on Monday. The company has a market cap of $3.85 billion, a price-to-earnings ratio of -14.39 and a beta of 1.54. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $24.69 and a 200-day simple moving average of $24.34. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $30.58.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CNTA shares. Truist Financial lifted their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Wolfe Research assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $39.80.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at $1,735,805.25. The trade was a 52.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 233,186 shares of company stock valued at $6,082,890 in the last quarter. Company insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. raised its position in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the last quarter. Knott David M Jr acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $100,000. Finally, Virtus Investment Advisers LLC grew its position in shares of Centessa Pharmaceuticals by 6.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after buying an additional 583 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.